Respiratory Syncytial Virus Infections, Respiratory Tract Infections
Conditions
Brief summary
Infection with human respiratory syncytial (RS) virus is the most common cause of hospital stay due to pediatric lower respiratory tract infection. An exaggerated immune response contributes to the pathogenesis and small children may have over reactive airways for a long time after an infection. New research has shown that polymorphonuclear leukocytes (PMNs) are stimulated by the virus. Besides fighting the infection they also cause collateral damage to the host. Among other mechanisms PMNs stimulates mucus formation that affects breathing. They also secrete enzymes, toxic proteins and free radicals that may cause harm to lung tissue and airways. The current project strives towards identifying and quantifying inflammatory mediators in sputum, urine and blood of children with severe RS-virus infection. The ultimate aim of the project is to, in detail, describe proteins contributing to the pathogenesis of the disease.
Interventions
OTHERRS-virus infection
The intervention consists of lower respiratory tract infection due to RS-virus
Sponsors
Swedish University of Agricultural Sciences
Uppsala University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Admission to pediatric intensive care unit * Clinical need for invasive ventilation * Clinical need for intravascular catheterization * Clinical need for urine bladder catheterization * Patients with verified or suspected RS-virus-infection or no respiratory tract infection (control group)
Exclusion criteria
• Chronic inflammatory lung disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Levels of inflammatory mediators in sputum | Up to three weeks | Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry |
| Levels of inflammatory mediators in blood | Up to three weeks | Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry |
| Levels of inflammatory mediators in urine | Up to three weeks | Simultaneous detection and quantification of hundreds of potential mediators using mass-spectrometry |
Secondary
| Measure | Time frame |
|---|---|
| Disease severity as measured by sequential organ failure assessment score (SOFA-score) | Up to 30-days |
| Lung function as measured in respirator | Up to 30-days |
| Lung function as measured by spirometry | Within 1 year |
Countries
Sweden
Outcome results
None listed